Warner Chilcott Targets Cadila Over Generic Asacol

Law360, San Diego (November 8, 2011, 9:58 PM EST) -- Warner Chilcott Co. LLC on Tuesday lodged a suit in Delaware federal court seeking to stop India-based Cadila Healthcare Ltd. and its U.S. unit from launching a generic version of inflammatory bowel disorder drug Asacol.

The Puerto Rico-based specialty pharmaceutical company brought its suit in response to the filing of an abbreviated new drug application by Cadila and Zydus Pharmaceuticals USA Inc. that seeks to market a generic mesalamine product before the expiration of Warner Chilcott’s patent.

The patent-in-suit, U.S. Patent Number 6,893,662, is titled “Pharmaceutical...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.